{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:21:51Z","timestamp":1790655711667,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82002962"],"award-info":[{"award-number":["82002962"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Department of Science and Technology of Jilin Province","award":["20210401076YY"],"award-info":[{"award-number":["20210401076YY"]}]},{"name":"the Norman Bethune Program","award":["2023B06"],"award-info":[{"award-number":["2023B06"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02683-8","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T12:13:09Z","timestamp":1743336789000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Enhancing KRAS G12D inhibitor sensitivity in pancreatic cancer through SHP2\/PI3K pathway"],"prefix":"10.1007","volume":"42","author":[{"given":"Man-Wei","family":"Hao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Xing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haicheng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"issue":"2","key":"2683_CR1","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1053\/j.gastro.2022.03.056","volume":"163","author":"LD Wood","year":"2022","unstructured":"Wood LD, Canto MI, Jaffee EM, et al. Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment. Gastroenterology. 2022;163(2):386\u2013402. https:\/\/doi.org\/10.1053\/j.gastro.2022.03.056.","journal-title":"Gastroenterology"},{"issue":"762","key":"2683_CR2","doi-asserted-by":"publisher","first-page":"eadj9366","DOI":"10.1126\/scitrans-lmed.adj9366","volume":"16","author":"L Chibaya","year":"2024","unstructured":"Chibaya L, DeMarco K, Lusi C, et al. Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer. Sci Transl Med. 2024;16(762):eadj9366. https:\/\/doi.org\/10.1126\/scitrans-lmed.adj9366.","journal-title":"Sci Transl Med."},{"issue":"261","key":"2683_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115857","volume":"5","author":"N Yang","year":"2023","unstructured":"Yang N, Fan ZY, Sun SY, et al. Discovery of highly potent and selective KRASG12C degraders by VHL-recruiting PROTACs for the treatment of tumors with KRASG12C-Mutation. Eur J Med Chem. 2023;5(261): 115857. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115857.","journal-title":"Eur J Med Chem"},{"issue":"3","key":"2683_CR4","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1200\/JCO.2024.42.3_suppl.604","volume":"42","author":"J Li","year":"2024","unstructured":"Li J, Wang X, Huang Y, et al. Preliminary activity and safety results of KRAS G12C inhibitor glecirasib (JAB-21822) in patients with pancreatic cancer and other solid tumors. J Clin Oncol. 2024;42(3):604.","journal-title":"J Clin Oncol"},{"issue":"12","key":"2683_CR5","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/cac2.12204","volume":"41","author":"J Yang","year":"2021","unstructured":"Yang J, Xu R, Wang C, et al. Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review. Cancer Commun (Lond). 2021;41(12):1257\u201374. https:\/\/doi.org\/10.1002\/cac2.12204.","journal-title":"Cancer Commun (Lond)"},{"issue":"4","key":"2683_CR6","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s10555-020-09915-5","volume":"39","author":"J Timar","year":"2020","unstructured":"Timar J, Kashofer K. Molecular epidemiology and diagnostics of KRAS mutations in human cancer. Cancer Metastasis Rev. 2020;39(4):1029\u201338. https:\/\/doi.org\/10.1007\/s10555-020-09915-5.","journal-title":"Cancer Metastasis Rev"},{"issue":"8","key":"2683_CR7","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook CJ, Lyssiotis CA, Pasca di Magliano M, et al. Pancreatic cancer: advances and challenges. Cell. 2023;186(8):1729\u201354. https:\/\/doi.org\/10.1016\/j.cell.2023.02.014.","journal-title":"Cell"},{"issue":"1","key":"2683_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA Cancer J Clin"},{"issue":"6700","key":"2683_CR9","doi-asserted-by":"publisher","first-page":"eadk0775","DOI":"10.1126\/science.adk0775","volume":"384","author":"JA Klomp","year":"2024","unstructured":"Klomp JA, Klomp JE, Stalnecker CA, et al. Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers. Science. 2024;384(6700):eadk0775. https:\/\/doi.org\/10.1126\/science.adk0775.","journal-title":"Science"},{"issue":"41","key":"2683_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202404926","volume":"11","author":"YF Wang","year":"2024","unstructured":"Wang YF, Xu LS, Ling LJ, et al. Unraveling the CDK9\/PP2A\/ERK network in transcriptional pause release and complement activation in KRAS-mutant cancers. Adv Sci (Weinh). 2024;11(41): e2404926.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"2683_CR11","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41421-024-00699-4","volume":"10","author":"J Yang","year":"2024","unstructured":"Yang J, Wang QL, Wang GN, et al. A pan-KRAS degrader for the treatment of KRAS-mutant cancers. Cell Discov. 2024;10(1):70. https:\/\/doi.org\/10.1038\/s41421-024-00699-4.","journal-title":"Cell Discov"},{"issue":"10","key":"2683_CR12","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","volume":"28","author":"J Hallin","year":"2022","unstructured":"Hallin J, Bowcut V, Calinisan A, et al. Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nat Med. 2022;28(10):2171\u201382. https:\/\/doi.org\/10.1038\/s41591-022-02007-7.","journal-title":"Nat Med"},{"issue":"2","key":"2683_CR13","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1158\/2159-8290","volume":"13","author":"SB Kemp","year":"2023","unstructured":"Kemp SB, Cheng N, Markosyan N, et al. Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer. Cancer Discov. 2023;13(2):298\u2013311. https:\/\/doi.org\/10.1158\/2159-8290.","journal-title":"Cancer Discov"},{"key":"2683_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-024-03196-w","author":"SL Tinsley","year":"2024","unstructured":"Tinsley SL, Chianis ERD, Shelley RA, et al. KRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56alpha to initiate pancreatic cancer development. Oncogene. 2024. https:\/\/doi.org\/10.1038\/s41388-024-03196-w.","journal-title":"Oncogene"},{"issue":"1","key":"2683_CR15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12943-024-02157-x","volume":"23","author":"WJ McDaid","year":"2024","unstructured":"McDaid WJ, Wilson L, Adderley H, et al. The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer. Mol Cancer. 2024;23(1):253. https:\/\/doi.org\/10.1186\/s12943-024-02157-x.","journal-title":"Mol Cancer"},{"key":"2683_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semcancer.2021.05.010","volume":"85","author":"R Ullah","year":"2022","unstructured":"Ullah R, Yin Q, Snell AH, et al. RAF-MEK-ERK pathway in cancer evolution and treatment. Semin Cancer Biol. 2022;85:123\u201354. https:\/\/doi.org\/10.1016\/j.semcancer.2021.05.010.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"2683_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s43556-022-00110-2","volume":"3","author":"Q Li","year":"2022","unstructured":"Li Q, Li Z, Luo T, et al. Targeting the PI3K\/AKT\/mTOR and RAF\/MEK\/ERK pathways for cancer therapy. Mol Biomed. 2022;3(1):47. https:\/\/doi.org\/10.1186\/s43556-022-00110-2.","journal-title":"Mol Biomed"},{"issue":"1","key":"2683_CR18","doi-asserted-by":"publisher","first-page":"5439","DOI":"10.1038\/s41467-020-19288-6","volume":"11","author":"S Hamarsheh","year":"2020","unstructured":"Hamarsheh S, Gro\u00df O, Brummer T, et al. Immune modulatory effects of oncogenic KRAS in cancer. Nat Commun. 2020;11(1):5439. https:\/\/doi.org\/10.1038\/s41467-020-19288-6.","journal-title":"Nat Commun"},{"issue":"1","key":"2683_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1021\/acs.jmedchem.9b01180","volume":"63","author":"BA Lanman","year":"2020","unstructured":"Lanman BA, Allen JR, Allen JG, et al. Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors. J Med Chem. 2020;63(1):52\u201365. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01180.","journal-title":"J Med Chem"},{"issue":"3","key":"2683_CR20","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40265-023-01839-y","volume":"83","author":"S Dhillon","year":"2023","unstructured":"Dhillon S. Adagrasib: first approval. Drugs. 2023;83(3):275\u201385. https:\/\/doi.org\/10.1007\/s40265-023-01839-y.","journal-title":"Drugs"},{"issue":"4","key":"2683_CR21","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","volume":"65","author":"X Wang","year":"2022","unstructured":"Wang X, Allen S, Blake JF, et al. Identification of MRTX1133, a noncovalent, potent, and selective KRASG12D inhibitor. J Med Chem. 2022;65(4):3123\u201333. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01688.","journal-title":"J Med Chem"},{"issue":"9","key":"2683_CR22","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.annonc.2021.06.001","volume":"32","author":"M Reck","year":"2021","unstructured":"Reck M, Carbone DP, Garassino M, et al. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol. 2021;32(9):1101\u201310. https:\/\/doi.org\/10.1016\/j.annonc.2021.06.001.","journal-title":"Ann Oncol"},{"issue":"12","key":"2683_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110993","volume":"39","author":"MB Ryan","year":"2022","unstructured":"Ryan MB, Coker O, Sorokin A, et al. KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy. Cell Rep. 2022;39(12): 110993. https:\/\/doi.org\/10.1016\/j.celrep.2022.110993.","journal-title":"Cell Rep"},{"issue":"7781","key":"2683_CR24","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575(7781):217\u201323. https:\/\/doi.org\/10.1038\/s41586-019-1694-1.","journal-title":"Nature"},{"issue":"24","key":"2683_CR25","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1158\/0008-5472","volume":"83","author":"A Prahallad","year":"2023","unstructured":"Prahallad A, Weiss A, Voshol H, et al. CRISPR screening identifies mechanisms of resistance to KRASG12C and SHP2 inhibitor combinations in non-small cell lung cancer. Cancer Res. 2023;83(24):4130\u201341. https:\/\/doi.org\/10.1158\/0008-5472.","journal-title":"Cancer Res"},{"key":"2683_CR26","doi-asserted-by":"publisher","first-page":"100761","DOI":"10.1016\/j.drup.2021.100761","volume":"56","author":"SA Buck","year":"2021","unstructured":"Buck SA, Koolen SL, Mathijssen RH, de Wit R, van Soest RJ. Cross-resistance and drug sequence in prostate cancer. Drug Resist Updat. 2021;56:100761. https:\/\/doi.org\/10.1016\/j.drup.2021.100761.","journal-title":"Drug Resist Updat"},{"issue":"8","key":"2683_CR27","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","volume":"10","author":"V Amodio","year":"2020","unstructured":"Amodio V, Yaeger R, Arcella P, et al. EGFR Blockade reverts resistance to KRASG12C inhibition in colorectal cancer. Cancer Discov. 2020;10(8):1129\u201339. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0187.","journal-title":"Cancer Discov"},{"issue":"2","key":"2683_CR28","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1158\/1078-0432.CCR-18-0368","volume":"25","author":"S Misale","year":"2019","unstructured":"Misale S, Fatherree JP, Cortez E, et al. KRAS G12C NSCLC models are sensitive to direct targeting of KRAS in combination with PI3K inhibition. Clin Cancer Res. 2019;25(2):796\u2013807. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0368.","journal-title":"Clin Cancer Res"},{"key":"2683_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107966","volume":"230","author":"Y Song","year":"2022","unstructured":"Song Y, Zhao M, Zhang H, et al. Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials. Pharmacol Ther. 2022;230: 107966. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107966.","journal-title":"Pharmacol Ther"},{"key":"2683_CR30","doi-asserted-by":"publisher","first-page":"S459","DOI":"10.1016\/j.annonc.2023.09.1839","volume":"34","author":"J Wang","year":"2023","unstructured":"Wang J, Zhao J, Li X, et al. 653O Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in patients with KRAS p.G12C mutated solid tumors. Ann Oncol. 2023;34:S459.","journal-title":"Ann Oncol"},{"key":"2683_CR31","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/j.jtho.2022.07.022","volume":"17","author":"GS Falchook","year":"2022","unstructured":"Falchook GS, Li BT, Marrone KA, et al. OA0303 Sotorasib in combination with RMC-4630, a SHP2 inhibitor, in KRAS p.G12C-mutated NSCLC and other solid tumors. J Thorac Oncol. 2022;17:S8.","journal-title":"J Thorac Oncol"},{"issue":"18","key":"2683_CR32","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1158\/1078-0432.CCR-22-3947","volume":"29","author":"SM Gadgeel","year":"2023","unstructured":"Gadgeel SM, Miao JL, Riess JW, et al. Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC; SWOG S1507, NCT-02642042). Clin Cancer Res. 2023;29(18):3641\u20139.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2683_CR33","first-page":"1927","volume":"42","author":"DM Hyman","year":"2024","unstructured":"Hyman DM, Smit EF, Mazieres J, et al. Trametinib in combination with sotorasib in patients with KRAS G12C-mutated non-small cell lung cancer. J Clin Oncol. 2024;42(10):1927\u201336.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2683_CR34","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1158\/1078-0432.CCR-19-3523","volume":"26","author":"MB Ryan","year":"2020","unstructured":"Ryan MB, Fece de la Cruz F, Phat S, et al. Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition. Clin Cancer Res. 2020;26(7):1633\u201343. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3523.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"2683_CR35","doi-asserted-by":"publisher","first-page":"14837","DOI":"10.3390\/ijms241914837","volume":"24","author":"W Chen","year":"2023","unstructured":"Chen W, Park JI. Tumor cell resistance to the inhibition of BRAF and MEK1\/2. Int J Mol Sci. 2023;24(19):14837. https:\/\/doi.org\/10.3390\/ijms241914837.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2683_CR36","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1089\/thy.2017.0663","volume":"28","author":"F Borson-Chazot","year":"2018","unstructured":"Borson-Chazot F, Dantony E, Illouz F, et al. Effect of buparlisib, a pan-class I PI3K inhibitor, in refractory follicular and poorly differentiated thyroid cancer. Thyroid. 2018;28(9):1174\u20139. https:\/\/doi.org\/10.1089\/thy.2017.0663.","journal-title":"Thyroid"},{"issue":"17","key":"2683_CR37","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1158\/0008-5472","volume":"83","author":"MA Keats","year":"2023","unstructured":"Keats MA, Han JJW, Lee YH, et al. A nonconserved histidine residue on KRAS drives paralog selectivity of the KRASG12D inhibitor MRTX1133. Cancer Res. 2023;83(17):2816\u201323. https:\/\/doi.org\/10.1158\/0008-5472.","journal-title":"Cancer Res"},{"issue":"510","key":"2683_CR38","doi-asserted-by":"publisher","first-page":"eaaw7999","DOI":"10.1126\/scitranslmed.aaw7999","volume":"11","author":"M Molina-Arcas","year":"2019","unstructured":"Molina-Arcas M, Moore C, Rana S, et al. Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer. Sci Transl Med. 2019;11(510):eaaw7999. https:\/\/doi.org\/10.1126\/scitranslmed.aaw7999.","journal-title":"Sci Transl Med"},{"issue":"8","key":"2683_CR39","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.jtho.2021.04.015","volume":"16","author":"T Koga","year":"2021","unstructured":"Koga T, Suda K, Fujino T, et al. KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from in vitro experiments. J Thorac Oncol. 2021;16(8):1321\u201332. https:\/\/doi.org\/10.1016\/j.jtho.2021.04.015.","journal-title":"J Thorac Oncol"},{"issue":"7790","key":"2683_CR40","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41586-019-1884-x","volume":"577","author":"JY Xue","year":"2020","unstructured":"Xue JY, Zhao Y, Aronowitz J, et al. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. Nature. 2020;577(7790):421\u20135. https:\/\/doi.org\/10.1038\/s41586-019-1884-x.","journal-title":"Nature"},{"issue":"18","key":"2683_CR41","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1158\/0008-5472","volume":"83","author":"KCM Gulay","year":"2023","unstructured":"Gulay KCM, Zhang X, Pantazopoulou V, et al. Dual inhibition of KRASG12D and Pan-ERBB is synergistic in pancreatic ductal adenocarcinoma. Cancer Res. 2023;83(18):3001\u201312. https:\/\/doi.org\/10.1158\/0008-5472.","journal-title":"Cancer Res"},{"issue":"4","key":"2683_CR42","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1158\/1078-0432.CCR-23-2098","volume":"30","author":"D Wei","year":"2024","unstructured":"Wei D, Wang L, Zuo X, et al. A small molecule with big impact: MRTX1133 Targets the KRASG12D mutation in pancreatic cancer. Clin Cancer Res. 2024;30(4):655\u201362. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2098.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2683_CR43","doi-asserted-by":"publisher","first-page":"4523","DOI":"10.62347\/DVXL1377","volume":"14","author":"V Tajiknia","year":"2024","unstructured":"Tajiknia V, Pinho-Schwermann M, Srinivasan PR, et al. Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G12D inhibitor MRTX1133 in CRC and pancreatic cancer cells independent of G12D mutation. Am J Cancer Res. 2024;14(9):4523\u201336. https:\/\/doi.org\/10.62347\/DVXL1377.","journal-title":"Am J Cancer Res"},{"issue":"10","key":"2683_CR44","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.21873\/anticanres.16629","volume":"43","author":"M Kataoka","year":"2023","unstructured":"Kataoka M, Kitazawa M, Nakamura S, et al. Cetuximab enhances the efficacy of MRTX1133, a novel KRASG12D inhibitor, in colorectal cancer treatment. Anticancer Res. 2023;43(10):4341\u20138. https:\/\/doi.org\/10.21873\/anticanres.16629.","journal-title":"Anticancer Res"},{"issue":"4","key":"2683_CR45","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.21037\/jgo-24-255","volume":"15","author":"M Haidar","year":"2024","unstructured":"Haidar M, Jacquemin P. MRTX1133\u2019s promise for treating KRASG12D-mutant pancreatic cancer. J Gastrointest Oncol. 2024;15(4):2002\u20135. https:\/\/doi.org\/10.21037\/jgo-24-255. (Epub 2024 Aug 5).","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"2683_CR46","doi-asserted-by":"publisher","first-page":"5151","DOI":"10.1038\/s41467-019-13086-5","volume":"10","author":"K Chan","year":"2019","unstructured":"Chan K, Robert F, Oertlin C, et al. eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma. Nat Commun. 2019;10(1):5151. https:\/\/doi.org\/10.1038\/s41467-019-13086-5.","journal-title":"Nat Commun"},{"issue":"1","key":"2683_CR47","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s13046-022-02542-8","volume":"41","author":"K Fooks","year":"2022","unstructured":"Fooks K, Galicia-Vazquez G, Gife V, et al. EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax. J Exp Clin Cancer Res. 2022;41(1):340. https:\/\/doi.org\/10.1186\/s13046-022-02542-8.","journal-title":"J Exp Clin Cancer Res"},{"issue":"9","key":"2683_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133610","volume":"10","author":"JL Anderson","year":"2015","unstructured":"Anderson JL, Park A, Akiyama R, et al. evaluation of in vitro activity of the class I PI3K inhibitor buparlisib (BKM120) in pediatric bone and soft tissue sarcomas. PLoS ONE. 2015;10(9): e0133610. https:\/\/doi.org\/10.1371\/journal.pone.0133610.","journal-title":"PLoS ONE"},{"issue":"9","key":"2683_CR49","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","volume":"41","author":"KK Mahadevan","year":"2023","unstructured":"Mahadevan KK, McAndrews KM, LeBleu VS, et al. KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells. Cancer Cell. 2023;41(9):1606-1620.e8. https:\/\/doi.org\/10.1016\/j.ccell.2023.07.002.","journal-title":"Cancer Cell"},{"issue":"20","key":"2683_CR50","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1038\/s41388-023-02676-9","volume":"42","author":"J Feng","year":"2023","unstructured":"Feng J, Hu Z, Xia X, et al. Feedback activation of EGFR\/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer. Oncogene. 2023;42(20):1620\u201333. https:\/\/doi.org\/10.1038\/s41388-023-02676-9.","journal-title":"Oncogene"},{"issue":"1","key":"2683_CR51","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s10020-024-00972-y","volume":"30","author":"C Xu","year":"2024","unstructured":"Xu C, Lin W, Zhang Q, et al. MGST1 facilitates novel KRASG12D inhibitor resistance in KRASG12D-mutated pancreatic ductal adenocarcinoma by inhibiting ferroptosis. Mol Med. 2024;30(1):199. https:\/\/doi.org\/10.1186\/s10020-024-00972-y.","journal-title":"Mol Med"},{"issue":"21","key":"2683_CR52","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1158\/0008-5472.CAN-23-3574","volume":"84","author":"JH Becker","year":"2024","unstructured":"Becker JH, Metropulos AE, Spaulding C, et al. Targeting BCL2 with venetoclax enhances the efficacy of the KRASG12D inhibitor MRTX1133 in pancreatic cancer. Can Res. 2024;84(21):3629\u201339. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-3574.","journal-title":"Can Res"},{"key":"2683_CR53","doi-asserted-by":"publisher","first-page":"7657","DOI":"10.2147\/CMAR.S214697","volume":"11","author":"C Wang","year":"2019","unstructured":"Wang C, Zhao N, Zheng Q, et al. BHLHE41 promotes U87 and U251 cell proliferation via ERK\/cyclinD1 signaling pathway. Cancer Manag Res. 2019;11:7657\u201372. https:\/\/doi.org\/10.2147\/CMAR.S214697.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"2683_CR54","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1158\/0008-5472","volume":"83","author":"CM Goodwin","year":"2023","unstructured":"Goodwin CM, Waters AM, Klomp JE, et al. Combination therapies with CDK4\/6 inhibitors to treat KRAS-mutant pancreatic cancer. Cancer Res. 2023;83(1):141\u201357. https:\/\/doi.org\/10.1158\/0008-5472.","journal-title":"Cancer Res"},{"issue":"2","key":"2683_CR55","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s13105-020-00734-4","volume":"76","author":"X Meng","year":"2020","unstructured":"Meng X, Ma J, Wang B, et al. Long non-coding RNA OIP5-AS1 promotes pancreatic cancer cell growth through sponging miR-342-3p via AKT\/ERK signaling pathway. J Physiol Biochem. 2020;76(2):301\u201315. https:\/\/doi.org\/10.1007\/s13105-020-00734-4.","journal-title":"J Physiol Biochem"},{"key":"2683_CR56","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.bbrc.2023.04.080","volume":"664","author":"F Wu","year":"2023","unstructured":"Wu F, He J, Deng Q, et al. Neuroglobin inhibits pancreatic cancer proliferation and metastasis by targeting the GNAI1\/EGFR\/AKT\/ERK signaling axis. Biochem Biophys Res Commun. 2023;664:108\u201316. https:\/\/doi.org\/10.1016\/j.bbrc.2023.04.080.","journal-title":"Biochem Biophys Res Commun"},{"key":"2683_CR57","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.coph.2018.04.009","volume":"41","author":"JN Mills","year":"2018","unstructured":"Mills JN, Rutkovsky AC, Giordano A. Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen\/aromatase inhibitors. Curr Opin Pharmacol. 2018;41:59\u201365. https:\/\/doi.org\/10.1016\/j.coph.2018.04.009.","journal-title":"Curr Opin Pharmacol"},{"issue":"10","key":"2683_CR58","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.jgg.2022.02.001","volume":"49","author":"X Lu","year":"2022","unstructured":"Lu X, Shi S, Wu C, et al. The shikimate pathway regulates programmed cell death. J Genet Genom. 2022;49(10):943\u201351. https:\/\/doi.org\/10.1016\/j.jgg.2022.02.001.","journal-title":"J Genet Genom"},{"issue":"4","key":"2683_CR59","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s10495-008-0300-z","volume":"14","author":"A Frenzel","year":"2009","unstructured":"Frenzel A, Grespi F, Chmelewskij W, et al. Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis. 2009;14(4):584\u201396. https:\/\/doi.org\/10.1007\/s10495-008-0300-z.","journal-title":"Apoptosis"},{"issue":"10","key":"2683_CR60","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1021\/ml200156t","volume":"2","author":"MT Burger","year":"2011","unstructured":"Burger MT, Pecchi S, Wagman A, et al. Identification of NVP-BKM120 as a potent, selective, orally bioavailable class I PI3 kinase inhibitor for treating cancer. ACS Med Chem Lett. 2011;2(10):774\u20139. https:\/\/doi.org\/10.1021\/ml200156t.","journal-title":"ACS Med Chem Lett"},{"issue":"3","key":"2683_CR61","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/1878-0261.13577","volume":"18","author":"T Sugawara","year":"2024","unstructured":"Sugawara T, Nevedomskaya E, Heller S, et al. Dual targeting of the androgen receptor and PI3K\/AKT\/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis. Mol Oncol. 2024;18(3):726\u201342. https:\/\/doi.org\/10.1002\/1878-0261.13577.","journal-title":"Mol Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02683-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02683-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02683-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T01:58:12Z","timestamp":1746151092000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02683-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":61,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["2683"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02683-8","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"3 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent statement"}}],"article-number":"139"}}